Candriam SCA’s Krystal Biotech KRYS Stock Holding History

Candriam SCA’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-55,000	Closed	-$6.82M	–	717
2023 Q4	$6.82M	Sell	55,000 -15,000	-21%	-$1.66M	0.05%	301
2023 Q3	$8.12M	Hold	70,000	–	–	0.06%	255
2023 Q2	$8.22M	Sell	70,000 -22,000	-24%	-$2.25M	0.06%	266
2023 Q1	$6.78M	Buy	+92,000	New	+$7.23M	0.05%	309

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Candriam SCA's KRYS Position: Q1 2024 in Review

Candriam SCA sold out of Krystal Biotech (KRYS) in Q1 2024, closing a stake of 55,000 shares — an estimated $6.82M sold.

Candriam SCA first reported a position in KRYS in Q1 2023 and held it in 4 quarters. The position peaked at $8.22M in Q2 2023. 234 funds tracked by Wall St. Rank hold KRYS as of Q1 2024.

Candriam SCA reported no remaining Krystal Biotech position as of Q1 2024 after selling out during the quarter.
Candriam SCA sold 55,000 Krystal Biotech shares in Q1 2024, an estimated $6.82M.
Candriam SCA first reported a position in Krystal Biotech in Q1 2023 and held it in 4 quarters.
Candriam SCA's Krystal Biotech position peaked at $8.22M in Q2 2023.
234 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2024.

Based on Candriam SCA's 13F filing for Q1 2024, filed 6 May 2024.